Emistat Oral Solution 50ml

Uses of Emistat Oral Solution

• Used to prevent nausea and vomiting in children caused by cancer chemotherapy, radiation therapy, and surgery

Side Effects of Emistat Oral Solution

• Diarrhea
• Fatigue
• Headache
• Constipation
• Fast or slow or irregular heartbeat
• Chills
• Dry mouth
• Anxiety
• Dizziness

How Emistat Oral Solution works?

Emistat Oral Solution is a serotonin 5-HT3 receptor antagonist (specific chemical receptor), and it works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting.

Quick Suggestions

• You have been prescribed Emistat Oral Solution for the prevention of nausea and vomiting caused after surgery or due to chemotherapy and radiotherapy.
• Unlike some other nausea medicines, the side effects of Emistat Oral Solution are relatively mild.
• It is fast-acting and starts working within 30 minutes.
• If you vomit within one hour of taking a dose, take another dose.
• Avoid heavy meals and try eating small nourishing snacks throughout the day. Also, sip water regularly to help avoid dehydration.

Indications of Emistat Oral Solution

Ondansetron is indicated for: 

• Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy
• Prevention of nausea and vomiting associated with radiotherapy
• Prevention of postoperative nausea and vomiting

Pharmacology

Emistat 4 may be a potent and intensely focused 5HT3 receptor antagonist. Its precise mechanism of operation under the influence of illness and heaving is unknown. By acting on vagal afferents via 5HT3 receptors, chemotherapeutic agents and radiotherapy may trigger the release of 5HT within the small intestine, initiating a spewing reflex. Ondansetron prevents this response from activating. The activation of vagal afferents may also release 5HT into the zone postrema, which is located on the floor of the fourth ventricle, which may further exacerbate emesis through a central mechanism. In this sense, the effect of ondansetron in the treatment of illness and the vomiting induced by cytotoxic chemotherapy and radiotherapy is probably caused by the antagonistic nature of 5HT3 receptors on neurons present in both the peripheral and central nervous systems. Although the mechanisms causing post-operative nausea and heaving are unknown, there may be shared pathways with cytotoxically induced illness and heaving.

Dosage & Administration of Emistat Oral Solution

• For the treatment of chemotherapy-induced nausea and vomiting, the recommended dose of Ondansetron Oral Solution for adults, geriatric patients, and children 12 years of age and older is 30 ml (24 mg) 30 minutes before the start of highly emetogenic chemotherapy and 10 ml (8 mg) 30 minutes before the start of moderately emetogenic chemotherapy. An additional 10 ml dose should be given 8 hours after the first dose, followed by one 10 ml dose twice a day (every 12 hours) for 1-2 days after completion of chemotherapy. For pediatric patients (4-11 years), the recommended dose is 5 ml (4 mg) 30 minutes before the start of chemotherapy, with two additional doses given 4 and 8 hours after the first dose, followed by 5 ml of the oral solution administered three times a day (every 8 hours) for 1-2 days after completion of chemotherapy.
• For radiotherapy-induced nausea and vomiting, the recommended dose of Ondansetron Oral Solution for adults, geriatric patients, and children 12 years of age and older is 10 ml (8 mg) three times daily. For total body radiation, 10 ml (8 mg) should be given 1 to 2 hours before each daily radiation session. For single high-dose radiation to the abdomen, one 10 ml dose should be given 1 to 2 hours before radiation, with subsequent doses every 8 hours after the first dose for 1-2 days after completion of radiation. For daily fractionated radiation to the abdomen, 10 ml (8 mg) should be given 1 to 2 hours before radiation, with subsequent doses every 8 hours after the first dose for each day radiation is given.
• For postoperative nausea and vomiting, the recommended dose of Ondansetron Oral Solution for adults, geriatric patients, and children 12 years of age and older is 20 ml (16 mg) given 1 hour before anesthesia.

Give this Emistat Oral solution to your kid exactly as directed by your doctor. Shake vigorously before using. It is intended for use by children. Your doctor will determine the appropriate dose based on your child's age, weight, and medical condition.

Interaction

Tramadol's analgesic effect may be reduced. Rifampicin and other CYP3A4 inducers may reduce ondansetron levels/effects. Concurrent use of QT-prolonging agents (e.g., antiarrhythmics) may result in additive QT interval prolongation. Cardiotoxic drugs may increase the risk of arrhythmias (e.g. anthracyclines). Potentially lethal: May increase apomorphine's hypotensive effect.

Contraindications

Contraindicated in patients known to have extreme touchiness to the medication or any of its components. Concomitant utilization of apomorphine.

Pregnancy & Lactation

Pregnancy Category B. Ondansetron is excreted within the breast milk of rats. It isn't known whether ondansetron is excreted in a human drain. Since numerous drugs are excreted in the human brain, caution ought to be worked out when ondansetron is managed by a nursing lady.

Precautions & Warnings

Touchiness responses, counting anaphylaxis and bronchospasm, have been detailed with or without known touchiness to other particular 5-HT3 receptor enemies. QT prolongation happens in a dose-dependent way.

Storage Conditions

Store in a cool and dry put below 30ºC. Secure from light. Keep out of reach of children.